IOVA — Iovance Biotherapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.41bn
- $1.12bn
- $263.50m
Annual cashflow statement for Iovance Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -342 | -396 | -444 | -372 | -391 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 86.6 | 96.7 | 70.8 | 111 | 79 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 24.6 | -2.89 | -6.52 | -123 | -24.3 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -228 | -293 | -362 | -353 | -302 |
| Capital Expenditures | -37.6 | -20.4 | -22.3 | -11.1 | -33.8 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 37.7 | 277 | -133 | -85.3 | 81.3 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 0.132 | 256 | -155 | -96.4 | 47.5 |
| Financing Cash Flow Items | — | -2.65 | -2.79 | -12.9 | -7.06 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 239 | 190 | 463 | 391 | 301 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 11.5 | 154 | -56.8 | -59.3 | 47 |